|Bid||0.00 x 900|
|Ask||0.00 x 900|
|Day's Range||126.66 - 127.30|
|52 Week Range||106.68 - 130.04|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.25%|
Abiomed’s (ABMD) net income has grown at a three-year and five-year average of 95.1% and 120.4%, respectively. The company’s pre-tax margin grew from 10.7% in 2013 to 20.5% in 2017. ABMD beat the medical device industry and the S&P 500 between 2013 and 2017. The market cap gained 680% between 2013 and 2017.
After a prolonged calm period, volatility roared back into the market with the sharp rise in Treasury yields, which led to the bloodbath in the stock market this week. This pushed the major indices into the red territory for the year and in the correction zone from the latest peak.Source: Investment Zen via Flickr (Modified)
After success in the company's phase 1/2 trial with BMN 270, an investigational gene therapy for hemophilia A, BioMarin Pharmaceuticals (BMRN) is expected to start phase 3 trials.
With the Edwards Intuity Elite valve system, Edwards Lifesciences aims to offer a minimally invasive therapy to complex aortic stenosis patients.
Of the 18 analysts tracking Southwest Airlines (LUV), six (33.3%) have rated the stock a "strong buy," and another six (33.3%) have recommended a "buy."
Given Apple's stock outperformance this year, it's not surprising to see it at the top of many equity growth funds' holdings.
A total of 20 analysts were analyzing BioMarin Pharmaceuticals in July 2017. Six analysts recommended a “strong buy,” while nine analysts suggested a “buy.”
UAA is covered by 34 Wall Street analysts who together rate the company a 2.9 on a scale of 1.0 for "strong buy" to 5.0 for "sell."
After posting better 1Q17 earnings on April 25, Chipotle's stock price rose to $496.14 by May 16, 2017. Since then, it has experienced downward momentum.